A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin

Marjan de Groot; Daisy I. Picavet; Arno W. R. van Kuijk; Paul P. Tak; Jan D. Bos; Menno A. de Rie; Marcel B. M. Teunissen

doi:https://doi.org/10.1159/000343290

A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin

Marjan de Groot, Daisy I. Picavet, Arno W. R. van Kuijk, Paul P. Tak, Jan D. Bos, Menno A. de Rie, Marcel B. M. Teunissen

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Abstract

Background: There is a need for biomarkers to screen the effectiveness of (novel) therapeutic agents for psoriasis at an early stage. Objective: We aimed to determine which of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy. Methods: Twenty-two psoriatic arthritis patients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin biopsies at baseline and after 4 weeks of treatment. Results: CD161+ and elastase+ dermal cells in lesional skin were significantly reduced upon 4 weeks of successful adalimumab treatment compared with placebo. Conclusion: Early improvement of psoriasis lesions during adalimumab therapy is associated with a marked reduction of infiltrated dermal CD161+ T cells and elastase+ neutrophils, suggesting that these parameters could be used as biomarkers to monitor early changes after active treatment in small proof-of-concept studies of short duration. Copyright (c) 2012 S. Karger AG, Basel

Original language	English
Pages (from-to)	298-303
Journal	Dermatology (Basel, Switzerland)
Volume	225
Issue number	4
DOIs	https://doi.org/10.1159/000343290
Publication status	Published - 2012

Access to Document

https://doi.org/10.1159/000343290

Cite this

de Groot, M., Picavet, D. I., van Kuijk, A. W. R., Tak, P. P., Bos, J. D., de Rie, M. A., & Teunissen, M. B. M. (2012). A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin. Dermatology (Basel, Switzerland), 225(4), 298-303. https://doi.org/10.1159/000343290

@article{c7245a1b202b4d29898542704795fef0,

title = "A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin",

abstract = "Background: There is a need for biomarkers to screen the effectiveness of (novel) therapeutic agents for psoriasis at an early stage. Objective: We aimed to determine which of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy. Methods: Twenty-two psoriatic arthritis patients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin biopsies at baseline and after 4 weeks of treatment. Results: CD161+ and elastase+ dermal cells in lesional skin were significantly reduced upon 4 weeks of successful adalimumab treatment compared with placebo. Conclusion: Early improvement of psoriasis lesions during adalimumab therapy is associated with a marked reduction of infiltrated dermal CD161+ T cells and elastase+ neutrophils, suggesting that these parameters could be used as biomarkers to monitor early changes after active treatment in small proof-of-concept studies of short duration. Copyright (c) 2012 S. Karger AG, Basel",

author = "{de Groot}, Marjan and Picavet, {Daisy I.} and {van Kuijk}, {Arno W. R.} and Tak, {Paul P.} and Bos, {Jan D.} and {de Rie}, {Menno A.} and Teunissen, {Marcel B. M.}",

year = "2012",

doi = "https://doi.org/10.1159/000343290",

language = "English",

volume = "225",

pages = "298--303",

journal = "Dermatology (Basel, Switzerland)",

issn = "1018-8665",

publisher = "S. Karger AG",

number = "4",

}

de Groot, M, Picavet, DI, van Kuijk, AWR, Tak, PP, Bos, JD, de Rie, MA & Teunissen, MBM 2012, 'A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin', Dermatology (Basel, Switzerland), vol. 225, no. 4, pp. 298-303. https://doi.org/10.1159/000343290

A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin. / de Groot, Marjan; Picavet, Daisy I.; van Kuijk, Arno W. R. et al.
In: Dermatology (Basel, Switzerland), Vol. 225, No. 4, 2012, p. 298-303.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin

AU - de Groot, Marjan

AU - Picavet, Daisy I.

AU - van Kuijk, Arno W. R.

AU - Tak, Paul P.

AU - Bos, Jan D.

AU - de Rie, Menno A.

AU - Teunissen, Marcel B. M.

PY - 2012

Y1 - 2012

N2 - Background: There is a need for biomarkers to screen the effectiveness of (novel) therapeutic agents for psoriasis at an early stage. Objective: We aimed to determine which of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy. Methods: Twenty-two psoriatic arthritis patients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin biopsies at baseline and after 4 weeks of treatment. Results: CD161+ and elastase+ dermal cells in lesional skin were significantly reduced upon 4 weeks of successful adalimumab treatment compared with placebo. Conclusion: Early improvement of psoriasis lesions during adalimumab therapy is associated with a marked reduction of infiltrated dermal CD161+ T cells and elastase+ neutrophils, suggesting that these parameters could be used as biomarkers to monitor early changes after active treatment in small proof-of-concept studies of short duration. Copyright (c) 2012 S. Karger AG, Basel

AB - Background: There is a need for biomarkers to screen the effectiveness of (novel) therapeutic agents for psoriasis at an early stage. Objective: We aimed to determine which of the changes in psoriatic skin correlates best with clinical improvement 4 weeks after effective adalimumab therapy. Methods: Twenty-two psoriatic arthritis patients were randomized to receive adalimumab or placebo. T cell numbers and markers of innate immunity were estimated in lesional and nonlesional skin biopsies at baseline and after 4 weeks of treatment. Results: CD161+ and elastase+ dermal cells in lesional skin were significantly reduced upon 4 weeks of successful adalimumab treatment compared with placebo. Conclusion: Early improvement of psoriasis lesions during adalimumab therapy is associated with a marked reduction of infiltrated dermal CD161+ T cells and elastase+ neutrophils, suggesting that these parameters could be used as biomarkers to monitor early changes after active treatment in small proof-of-concept studies of short duration. Copyright (c) 2012 S. Karger AG, Basel

U2 - https://doi.org/10.1159/000343290

DO - https://doi.org/10.1159/000343290

M3 - Article

C2 - 23257348

SN - 1018-8665

VL - 225

SP - 298

EP - 303

JO - Dermatology (Basel, Switzerland)

JF - Dermatology (Basel, Switzerland)

IS - 4

ER -